Clinical Trial Supplies MarketSize, Share & Industry Analysis, 2026-2034By Service TypeBy Clinical PhaseBy Therapeutic AreaBy Drug TypeBy Temperature ConditionBy Route of AdministrationBy End UserBy Trial DesignBy Delivery Model
Full title & scope — all 9 axes with their segments
Clinical Trial Supplies Market Size, Share & Industry Analysis, By Service Type (Manufacturing, Packaging, Labeling and Kitting, Storage and Distribution, Comparator and Ancillary Sourcing, Supply Chain Management, Returns, Reconciliation and Destruction), By Clinical Phase (Phase I, Phase II, Phase III, Phase IV and Post-Marketing, Bioavailability and Bioequivalence Studies), By Therapeutic Area (Oncology, Cardiovascular and Metabolic, Central Nervous System, Infectious Diseases, Immunology and Inflammation, Respiratory, Rare and Orphan Diseases, Other Therapeutic Areas), By Drug Type (Small Molecules, Biologics, Vaccines, Cell and Gene Therapies, Medical Devices and Combination Products), By Temperature Condition (Ambient, Refrigerated, Frozen, Ultra-Low, Cryogenic), By Route of Administration (Oral, Injectable, Topical, Inhalation, Ophthalmic, Other Routes), By End User (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, Medical Device Companies, Academic and Government Research Institutes), By Trial Design (Open-Label Trials, Single-Blind Trials, Double-Blind Trials, Adaptive and Platform Trials), By Delivery Model (Depot-to-Site, Direct-to-Patient, Hybrid and Decentralized Models), and Regional Forecast, 2026-2034
Market outlook, key takeaways, drivers and challenges for the report period.
- 01By Service TypeManufacturing · Packaging, Labeling and Kitting · Storage and Distribution
- 02By Clinical PhasePhase I · Phase II · Phase III
- 03By Therapeutic AreaOncology · Cardiovascular and Metabolic · Central Nervous System
- 04By Drug TypeSmall Molecules · Biologics · Vaccines
- 05By Temperature ConditionAmbient · Refrigerated · Frozen
- 06By Route of AdministrationOral · Injectable · Topical
- 07By End UserPharmaceutical Companies · Biotechnology Companies · Contract Research Organizations
- 08By Trial DesignOpen-Label Trials · Single-Blind Trials · Double-Blind Trials
- 09By Delivery ModelDepot-to-Site · Direct-to-Patient · Hybrid and Decentralized Models
- 10By Region
Market Analysis & Outlook
Clinical trial supplies are the investigational medicines, comparators, placebos and ancillary materials that sponsors need to run a study, together with the services that make, label, store, ship, track and finally reconcile or destroy them. They take the form of oral, injectable and other dosage forms handled at conditions from ambient to cryogenic, and of kits prepared for each site or patient. Buyers are pharmaceutical and biotechnology sponsors, contract research organizations, device companies and research institutes.
Growth of 9% a year carries the global clinical trial supplies market from USD 4.6 billion in 2025 to USD 9.96 billion in 2034. The full series behind that rate covers USD 2.95 billion in 2020, USD 4.2 billion in 2024, USD 5 billion in 2026 and USD 7.05 billion in 2030, with 2025 as the base year.
The service type mix shifts over the period. Storage and Distribution is the largest line in 2025 at USD 1.29 billion, a 28% share, moving to USD 2.74 billion and 27.5% by 2034. Supply Chain Management grows fastest at 10.84%, taking its share from 12% to 14%, while Packaging, Labeling and Kitting grows slowest at 8.15%. Comparator and Ancillary Sourcing and Supply Chain Management take share over the period; Manufacturing, Packaging, Labeling and Kitting, Storage and Distribution and Returns, Reconciliation and Destruction give it up while still growing in absolute terms.
Cut by clinical phase, the largest line is Phase III: 47% of 2025 revenue, worth USD 2.16 billion, and 44.5% at USD 4.43 billion by 2034. Phase IV and Post-Marketing grows faster at 10.1% against 8.31%, moving from 15% of revenue to 16.5% by 2034. Both this axis and the service type one divide the same revenue, which is why they are alternative views, not components.
Geographically, 40.2% of 2025 revenue sits in North America (USD 1.85 billion rising to USD 3.68 billion) ahead of Europe at 28% and USD 1.29 billion. Middle East and Africa is smallest, at 4.5%. Because Asia Pacific take share, the revenue added by 2034 concentrates instead of spreading across all five regions.
Coverage extends to five regions, six service type lines and nine segmentation axes over the full fifteen years. The 2025 total itself is a triangulation of published figures and category proxies, short of a directly sourced total, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.
Market Size, 2020–2034
USD BillionRevenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- A forecast-period rate of 9% takes the market from USD 4.6 billion in 2025 to USD 9.96 billion in 2034, against 9.29% recorded over the 2020-2025 historical period.
- 28% of 2025 revenue sits in Storage and Distribution (USD 1.29 billion) and it remains the largest service type line in 2034 at USD 2.74 billion and 27.5%.
- Supply Chain Management is the fastest-growing line at 10.84%, lifting its share from 12% in 2025 to 14% in 2034 and its revenue from USD 0.55 billion to USD 1.39 billion.
- The bull case puts 2034 revenue at USD 10.88 billion and the bear case at USD 8.51 billion, either side of the USD 9.96 billion base case, each with its own stated assumption in the full report.
- North America holds 40.2% of global revenue in 2025 at USD 1.85 billion, the largest of the five regions tracked, and reaches USD 3.68 billion by 2034.
- Within North America, the United States is the worked country example, at USD 1.62 billion in 2025; 87.6% of regional revenue in the base year, and USD 3.22 billion by 2034.
- Every line on all nine segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.
Market Trends
Revenue Share, By service type
Base year 2025Storage and Distribution leads with 28.0% of service type segment revenue.
Share of service type segment revenue, most recent base year.
Three movements define the forecast period in the global clinical trial supplies market: how the service type mix changes, where regional weight shifts, and the rate at which the total compounds.
All three are changes in mix, not in direction: nothing contracts, and the movement is in which lines and regions absorb the new revenue.
Composition shifts on the service type axis. 10.84% against 8.15%: that gap, between Supply Chain Management and Packaging, Labeling and Kitting, is the largest on the service type axis. By 2034 the two sit at 14% and 20.5% of revenue, against 12% and 22% in 2025. In absolute terms Supply Chain Management rises from USD 0.55 billion to USD 1.39 billion, while Packaging, Labeling and Kitting rises from USD 1.01 billion to USD 2.04 billion. Both grow; the gap is wide enough to reshape the mix inside a single forecast window.
Regional weight shifts toward Asia Pacific. Asia Pacific moves from 21.8% of revenue in 2025 to 26% in 2034, worth USD 1 billion rising to USD 2.59 billion. The remaining regions grow in absolute terms while giving up share: North America at 40.2% moving to 37%, Europe at 28% moving to 27%, Latin America at 5.5% moving to 5.5%, Middle East and Africa at 4.5% moving to 4.5%. That makes the regional split worth reading directly instead of scaling from the global rate: the same market rate produces different outcomes depending on where a supplier's revenue sits.
Growth compounds at 9% without a step change. Fifteen years of revenue run USD 2.95 billion in 2020, USD 4.2 billion in 2024, USD 4.6 billion in 2025, USD 5 billion in 2026, USD 7.05 billion in 2030 and USD 9.96 billion in 2034. The forecast rate of 9% sits against 9.29% over the historical period, so the projection extends an observed trend instead of proposing a new one. The risk in the number sits in the mix assumptions, not in whether the market grows at all, which is where the service type and regional sections come in.
Market Growth Factors
Growth is concentrated in Supply Chain Management
Market Drivers
3- 01Growth is concentrated in Supply Chain Management
10.84% growth in Supply Chain Management, against 9% for the market as a whole, moves it from USD 0.55 billion and 12% of revenue in 2025 to USD 1.39 billion and 14% in 2034. Nothing else on the axis grows as fast (Packaging, Labeling and Kitting manages 8.15%) so the blended 9% is carried by this one line instead of shared across them. Where a supplier sits on this axis therefore decides whether it grows with the market or below it.
- 02Regional weight, not regional count
North America is the largest region at USD 1.85 billion in 2025, 40.2% of global revenue, and reaches USD 3.68 billion by 2034 while holding 37%. Europe adds a further 28% at USD 1.29 billion, reaching USD 2.69 billion. Most of the base and most of the growth sit in those two, and a plan spread evenly across regions therefore over-invests outside them.
- 03The trend is already in the record
USD 2.95 billion in 2020, USD 4.2 billion in 2024 and USD 4.6 billion in 2025: 9.29% compound growth before the forecast period even begins. From there the forecast carries 9% through to USD 9.96 billion in 2034. With the trajectory already demonstrated over fifteen years, what remains uncertain is the mix, not the direction, which is where the segment and regional sections do the work.
Growth drivers
| # | Growth driver | Impact | Gross contribution (USD Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Growth in biologics and cell and gene therapy pipelines | High | +1.75 | High | High | High |
| 2 | Sponsor outsourcing of clinical supply and logistics | High | +1.5 | High | High | Medium |
| 3 | Adoption of direct-to-patient and decentralized trial models | Medium-High | +1.05 | Medium | High | High |
| 4 | Rising trial activity in oncology and rare diseases | Medium-High | +1 | High | Medium | Medium |
| 5 | Expansion of trial sites in Asia Pacific | Medium | +0.5 | Medium | Medium | Medium |
| 6 | Others | Low | +0.46 | Low | Low | Low |
| Total | +6.26 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (USD Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Cold-chain cost and capacity limits | Medium-High | −0.4 | High | Medium | Medium |
| 2 | Divergent import, export and release rules across countries | Medium | −0.3 | Medium | Medium | Low |
| 3 | Pricing pressure and trial cancellations from sponsor consolidation | Medium | −0.2 | Medium | Medium | Medium |
| Total | −0.9 | |||||
Drivers contribute 6.26 USD Billion and restraints remove 0.9 USD Billion, a net 5.36 USD Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
Growth in the global clinical trial supplies market comes from three measurable sources over 2026-2034: the market's own compounding at 9%, the share gained by faster-growing service type lines, and expansion in the regions taking a larger part of global revenue.
Restraining Factors
The bear case and what drives it
Market Restraints
2- 01The bear case and what drives it
The study's downside path assumes biotech funding stays tight, sponsors cancel or delay early-stage studies, and differing import and release rules slow adoption of decentralized delivery, and ends 2034 at USD 8.51 billion against the USD 9.96 billion base case, the same USD 4.6 billion base year, a slower forecast period.
- 02The largest line is not the fastest
Storage and Distribution carries 28% of 2025 revenue at USD 1.29 billion but compounds at 8.76% against 9% for the market, taking its share to 27.5% by 2034 even as revenue rises to USD 2.74 billion. Because it carries that much of the base, its pace holds the blended rate down more than any faster line lifts it.
Market Opportunities
Where the forecast could be beaten
Market Opportunities
2- 01Where the forecast could be beaten
A bull case of USD 10.88 billion by 2034, against USD 9.96 billion in the base case, turns on a single stated assumption: trial starts recover faster, cell and gene therapy programs reach late-stage studies sooner, and direct-to-patient delivery becomes routine in most large markets. The USD 4.6 billion 2025 base is common to both.
- 02The opening is on the service type axis, not the regional one
Share on the service type axis moves toward Supply Chain Management, from 12% in 2025 to 14% in 2034, on 10.84% growth against the market's 9% and revenue rising from USD 0.55 billion to USD 1.39 billion. Taking position there does not require displacing whoever holds Storage and Distribution, which is the harder and more expensive fight.
Market Challenges
The total depends on a single line
Market Challenges
2- 01The total depends on a single line
One line dominates: Storage and Distribution, at 28% of revenue in 2025 and 27.5% in 2034, worth USD 1.29 billion and USD 2.74 billion. Anything that changes demand for it changes the headline number; nothing else on the axis carries that weight.
- 02North America is largely the United States
Of North America's USD 1.85 billion in 2025, USD 1.62 billion (87.6%) comes from the United States alone, rising to USD 3.22 billion by 2034. Regional totals therefore move largely with one country's demand, so a regional forecast is more exposed to single-country conditions than its size alone suggests.
Segmentation Analysis
9 axesThe market is divided by service type and by clinical phase, therapeutic area, drug type, temperature condition, route of administration, end user, trial design and delivery model; nine axes in all. Every one of them divides the same revenue, which makes them views of one market from different commercial angles, not components of it.
There are six lines on the service type axis, and all of them grow in revenue between 2025 and 2034. What separates them is share: two gain it, the rest give it up.
By Service Type · 6 segments
Scale in Storage and Distribution and Growth in Supply Chain Management Define the Service type Axis
- Largest Storage and Distribution · 28%
- Fastest Supply Chain Management · 10.8%
- Moves most Supply Chain Management · +2 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Manufacturing | $0.83B | 18% | $1.74B | 17.5%-0.5 | 8.7% |
| Packaging, Labeling and Kitting | $1.01B | 22% | $2.04B | 20.5%-1.5 | 8.2% |
| Storage and Distribution | $1.29B | 28% | $2.74B | 27.5%-0.5 | 8.8% |
| Comparator and Ancillary Sourcing | $0.51B | 11% | $1.15B | 11.5%+0.5 | 9.4% |
| Supply Chain Management | $0.55B | 12% | $1.39B | 14%+2 | 10.8% |
| Returns, Reconciliation and Destruction | $0.41B | 9% | $0.90B | 9% | 9.1% |
Storage and distribution leads because every trial needs depots, temperature-controlled lanes and site deliveries regardless of its design, so the spend recurs across all studies. Supply chain management grows fastest as sponsors run more countries per study, add direct-to-patient legs and need forecasting, reconciliation and visibility tools for scarce, high-value investigational product. The order does not change: Storage and Distribution is still largest in 2034, and what moves is how much it holds. This is the axis the estimation prices in full, year by year, and the one the regional chapters cut against.
By Clinical Phase · 5 segments
Phase III Led by Clinical phase in 2025, with Phase IV and Post-Marketing Growing Fastest
- Largest Phase III · 47%
- Fastest Phase IV and Post-Marketing · 10.1%
- Moves most Phase III · -2.5 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Phase I | $0.51B | 11% | $1.15B | 11.5%+0.5 | 9.5% |
| Phase II | $0.96B | 21% | $2.19B | 22%+1 | 9.6% |
| Phase III | $2.16B | 47% | $4.43B | 44.5%-2.5 | 8.3% |
| Phase IV and Post-Marketing | $0.69B | 15% | $1.64B | 16.5%+1.5 | 10.1% |
| Bioavailability and Bioequivalence Studies | $0.28B | 6% | $0.55B | 5.5%-0.5 | 7.8% |
Phase III leads because late-stage studies enroll the most patients across the most sites and countries, and therefore consume the most product, packaging and distribution. Phase IV and post-marketing work grows fastest as sponsors run more real-world and label-expansion studies and regulators ask for longer follow-up on newer therapies. The order does not change: Phase III is still largest in 2034, and what moves is how much it holds.
By Therapeutic Area · 8 segments
By Therapeutic Area
- Largest Oncology · 31%
- Fastest Rare and Orphan Diseases · 13.1%
- Moves most Rare and Orphan Diseases · +3.5 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Oncology | $1.43B | 31% | $3.14B | 31.5%+0.5 | 9.1% |
| Cardiovascular and Metabolic | $0.64B | 14% | $1.24B | 12.5%-1.5 | 7.6% |
| Central Nervous System | $0.55B | 12% | $1.15B | 11.5%-0.5 | 8.5% |
| Infectious Diseases | $0.37B | 8% | $0.65B | 6.5%-1.5 | 6.5% |
| Immunology and Inflammation | $0.60B | 13% | $1.34B | 13.5%+0.5 | 9.3% |
| Respiratory | $0.23B | 5% | $0.40B | 4%-1 | 6.3% |
| Rare and Orphan Diseases | $0.41B | 9% | $1.24B | 12.5%+3.5 | 13.1% |
| Other Therapeutic Areas | $0.37B | 8% | $0.80B | 8% | 8.9% |
2025 to 2034 revenue and share by line: Oncology USD 1.43 billion to USD 3.14 billion (31% to 31.5%), Cardiovascular and Metabolic USD 0.64 billion to USD 1.24 billion (14% to 12.5%), Immunology and Inflammation USD 0.6 billion to USD 1.34 billion (13% to 13.5%), Central Nervous System USD 0.55 billion to USD 1.15 billion (12% to 11.5%), Rare and Orphan Diseases USD 0.41 billion to USD 1.24 billion (9% to 12.5%), Infectious Diseases USD 0.37 billion to USD 0.65 billion (8% to 6.5%), Other Therapeutic Areas USD 0.37 billion to USD 0.8 billion (8% to 8%), Respiratory USD 0.23 billion to USD 0.4 billion (5% to 4%). Rare and Orphan Diseases Outpaces the Axis While Oncology Holds the Largest Share Oncology leads because it has the largest number of active trials, long treatment durations and complex combination regimens that need careful supply planning. Rare and orphan diseases grow fastest as regulators and sponsors direct more development toward small populations, where each patient's supply is costly and shipments are spread across many countries. By 2034 Oncology is still ahead, making this a shift in weight, not a change of leader.
By Drug Type · 5 segments
Small Molecules Held the Dominant Share of the Drug type Segment in 2025
- Largest Small Molecules · 40%
- Fastest Cell and Gene Therapies · 16.3%
- Moves most Small Molecules · -7 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Small Molecules | $1.84B | 40% | $3.29B | 33%-7 | 6.7% |
| Biologics | $1.52B | 33% | $3.48B | 35%+2 | 9.6% |
| Vaccines | $0.37B | 8% | $0.70B | 7%-1 | 7.3% |
| Cell and Gene Therapies | $0.41B | 9% | $1.59B | 16%+7 | 16.3% |
| Medical Devices and Combination Products | $0.46B | 10% | $0.90B | 9%-1 | 7.7% |
Small molecules lead because most trials in progress still test oral and injectable chemical entities that ship at ordinary conditions. Cell and gene therapies grow fastest since each dose is patient-specific, needs cryogenic or tightly timed transport, and carries a much higher handling cost per shipment than conventional product. By 2034 the largest line is Biologics and no longer Small Molecules, the one axis here where the order actually changes.
By Temperature Condition · 5 segments
Scale in Refrigerated (2-8 C) and Growth in Cryogenic (Below -150 C) Define the Temperature condition Axis
- Largest Refrigerated (2-8 C) · 40%
- Fastest Cryogenic (Below -150 C) · 18%
- Moves most Ambient (15-25 C) · -6 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Ambient (15-25 C) | $1.75B | 38% | $3.18B | 32%-6 | 6.9% |
| Refrigerated (2-8 C) | $1.84B | 40% | $3.88B | 39%-1 | 8.6% |
| Frozen (-20 C) | $0.46B | 10% | $1.05B | 10.5%+0.5 | 9.6% |
| Ultra-Low (-80 C) | $0.37B | 8% | $1.05B | 10.5%+2.5 | 12.3% |
| Cryogenic (Below -150 C) | $0.18B | 4% | $0.80B | 8%+4 | 18% |
Refrigerated product leads because biologics, vaccines and many injectables need cold storage and cold-chain shipping on nearly every lane. Cryogenic handling grows fastest from a small base as cell and gene therapy programs multiply, needing dry shippers, liquid nitrogen storage and strict chain-of-custody records at each handover. Refrigerated (2-8 C) remains the largest line through 2034, so the axis changes in proportion, not in order.
By Route of Administration · 6 segments
Injectable Held the Dominant Share of the Route of administration Segment in 2025
- Largest Injectable · 44%
- Fastest Ophthalmic · 14.3%
- Moves most Oral · -7 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Oral | $1.84B | 40% | $3.28B | 33%-7 | 6.6% |
| Injectable | $2.03B | 44% | $4.98B | 50%+6 | 10.5% |
| Topical | $0.23B | 5% | $0.45B | 4.5%-0.5 | 7.7% |
| Inhalation | $0.23B | 5% | $0.50B | 5% | 9% |
| Ophthalmic | $0.09B | 2% | $0.30B | 3%+1 | 14.3% |
| Other Routes | $0.18B | 4% | $0.45B | 4.5%+0.5 | 10.7% |
Injectable products lead because biologics, oncology agents and most late-stage pipelines are delivered by injection or infusion, which adds device, kitting and cold-chain needs. Ophthalmic grows fastest from a small base as intravitreal and gene-based eye programs expand and require specialised packaging and short-dated handling. By 2034 Injectable is still ahead, making this a shift in weight, not a change of leader.
By End User · 5 segments
Pharmaceutical Companies Led by End user in 2025, with Biotechnology Companies Growing Fastest
- Largest Pharmaceutical Companies · 48%
- Fastest Biotechnology Companies · 10.9%
- Moves most Pharmaceutical Companies · -6 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Pharmaceutical Companies | $2.21B | 48% | $4.18B | 42%-6 | 7.3% |
| Biotechnology Companies | $1.10B | 24% | $2.79B | 28%+4 | 10.9% |
| Contract Research Organizations | $0.83B | 18% | $1.89B | 19%+1 | 9.6% |
| Medical Device Companies | $0.23B | 5% | $0.55B | 5.5%+0.5 | 10.2% |
| Academic and Government Research Institutes | $0.23B | 5% | $0.55B | 5.5%+0.5 | 10.2% |
Pharmaceutical companies lead because they sponsor the largest and most numerous late-stage programs and hold the budgets to outsource supply across several countries. Biotechnology companies grow fastest since they have thin internal logistics capacity and depend on specialist providers from the first dose through to returns. Pharmaceutical Companies remains the largest line through 2034, so the axis changes in proportion, not in order.
By Trial Design · 4 segments
Double-Blind Trials Led by Trial design in 2025, with Adaptive and Platform Trials Growing Fastest
- Largest Double-Blind Trials · 55%
- Fastest Adaptive and Platform Trials · 14.4%
- Moves most Adaptive and Platform Trials · +5.5 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Open-Label Trials | $1.29B | 28% | $2.69B | 27%-1 | 8.5% |
| Single-Blind Trials | $0.32B | 7% | $0.55B | 5.5%-1.5 | 6.2% |
| Double-Blind Trials | $2.53B | 55% | $5.18B | 52%-3 | 8.3% |
| Adaptive and Platform Trials | $0.46B | 10% | $1.54B | 15.5%+5.5 | 14.4% |
Double-blind trials lead because regulators expect them for pivotal efficacy evidence, and they need matched placebo or comparator supply, blinding labels and randomisation-linked shipments. Adaptive and platform trials grow fastest as sponsors adopt flexible designs that change arms and dosing mid-study, forcing frequent resupply and re-labeling. The order does not change: Double-Blind Trials is still largest in 2034, and what moves is how much it holds.
By Delivery Model · 3 segments
Direct-to-Patient Outpaces the Axis While Depot-to-Site Holds the Largest Share
- Largest Depot-to-Site · 78%
- Fastest Direct-to-Patient · 16%
- Moves most Depot-to-Site · -16 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Depot-to-Site | $3.59B | 78% | $6.18B | 62%-16 | 6.2% |
| Direct-to-Patient | $0.55B | 12% | $2.09B | 21%+9 | 16% |
| Hybrid and Decentralized Models | $0.46B | 10% | $1.69B | 17%+7 | 15.6% |
Depot-to-site leads because most trial visits still happen at investigator sites that receive stock from regional depots. Direct-to-patient grows fastest as sponsors seek to widen recruitment, cut patient travel and retain participants, which requires home delivery, courier coordination and tracking of product handled outside clinics. Depot-to-Site remains the largest line through 2034, so the axis changes in proportion, not in order.
Regional Insights
Regional Revenue Share
Base year 2025Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The largest region covered — 3.3 points of share move elsewhere by 2034, while revenue still grows 2.0×.
- Rank 1 of 5
- 2025 share 40.2%
- By 2034 36.9%
- Revenue $1.85B → $3.68B
In North America, 40.2% of global revenue puts 2025 at USD 1.85 billion and reaches USD 3.68 billion by 2034. By revenue it sits first across the study, and the ranking does not change between 2025 and 2034.
Its share moves to 37% by 2034, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.
Segment composition follows the global pattern: Storage and Distribution largest at 28% of 2025 revenue, Supply Chain Management fastest at 10.84%. Per-axis and per-country detail for North America sits in the full report.
United States
Sets the pace for North America at 87.6% of it, growing 2.0×.
- In region 1 of 2
- Of region 87.6%
- Of global 35.2%
- Revenue $1.62B → $3.22B
87.6% of North America's base-year revenue comes from the United States; USD 1.62 billion, rising to USD 3.22 billion by 2034. 87.6% of the region in 2025 means the regional figures are, in practice, a view of this market with others attached. Set against USD 1.85 billion and USD 3.68 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
Composition here matches the global split: the largest line is Storage and Distribution at 28% of 2025 revenue, easing to 27.5% by 2034, and the fastest is Supply Chain Management at 10.84%, from 12% to 14%. Its 87.6% weight in North America means those movements carry straight into the regional totals. Per-service type revenue for the United States appears on its own in the full report.
Clinical trial supplies in the United States fall under the Food and Drug Administration. Investigational drugs and biologics move under an Investigational New Drug application, and the sponsor remains responsible for the product. Manufacture follows current good manufacturing practice for investigational products, while the conduct of the study is governed by good clinical practice. Labelling must carry the statement that the product is limited by federal law to investigational use, and blinded or comparator supplies need traceable batch records. Importers and distributors of controlled substances also deal with the Drug Enforcement Administration, and cold chain handling must be documented for every shipment.
Thermo Fisher Scientific Inc., Catalent, Inc., Almac Group, PCI Pharma Services, Sharp Services, LLC, Marken Limited, Parexel International Corporation, Clinigen Group plc, Biocair International Ltd, Cryoport, Inc., Eurofins Scientific SE, Movianto GmbH, Yourway Transport, Inc., Ancillare, LP, World Courier (Cencora, Inc.), Bionical Emas Ltd, Azenta Life Sciences, Inc., Kuehne+Nagel International AG, DHL Group, Clario, Inc., Suvoda LLC, 4G Clinical, LLC, Recipharm AB and Piramal Pharma Limited are the suppliers covered in the United States. Storage and Distribution, at 28% of 2025 revenue, is where the volume sits, and Supply Chain Management, growing at 10.84%, is where position changes hands over the forecast period. Per-company positioning and share at country level are in the full report only.
Canada
2nd-largest in North America, growing 2.1×.
- In region 2 of 2
- Of region 9.2%
- Of global 3.7%
- Revenue $0.17B → $0.35B
3.7% of global revenue is generated in Canada; USD 0.17 billion in 2025, reaching USD 0.35 billion in 2034, and 9.2% of North America.
Europe Market Analysis
The 2nd-largest region covered — 1 point of share move elsewhere by 2034, while revenue still grows 2.1×.
- Rank 2 of 5
- 2025 share 28%
- By 2034 27%
- Revenue $1.29B → $2.69B
USD 1.29 billion of 2025 revenue is generated in Europe, 28% of the global clinical trial supplies market with USD 2.69 billion projected for 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.
By 2034 the share stands at 27%, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.
Storage and Distribution leads here as it does globally, at 28% of 2025 revenue, and Supply Chain Management again grows fastest at 10.84%. Europe is reported axis by axis and country by country in the full study.
Germany
The largest market in Europe, growing 2.0×.
- In region 1 of 3
- Of region 23.3%
- Of global 6.5%
- Revenue $0.30B → $0.60B
23.3% of Europe's base-year revenue comes from Germany; USD 0.3 billion, rising to USD 0.6 billion by 2034. At 23.3% of the region in 2025 it leads, but a majority of Europe's revenue is generated in other markets. Set against USD 1.29 billion and USD 2.69 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
Germany buys along the same lines as the market globally; Storage and Distribution first at 28% of 2025 revenue and 27.5% in 2034, Supply Chain Management fastest at 10.84% on a share moving from 12% to 14%. Because the country carries 23.3% of Europe, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Revenue by service type for Germany is reported separately in the full report.
Germany applies the EU Clinical Trials Regulation, with the Federal Institute for Drugs and Medical Devices and the Paul Ehrlich Institute reviewing applications for medicinal products, alongside the competent ethics committee. Investigational medicinal products must be made under EU good manufacturing practice, including its annex for investigational products, and a qualified person certifies each batch before release. Labelling follows the EU rules for investigational and auxiliary products, normally in German. Importing from outside the EU requires an authorised importer, and the supplier must keep documentation that lets the sponsor trace every unit from manufacture to patient.
Thermo Fisher Scientific Inc., Catalent, Inc., Almac Group, PCI Pharma Services, Sharp Services, LLC, Marken Limited, Parexel International Corporation, Clinigen Group plc, Biocair International Ltd, Cryoport, Inc., Eurofins Scientific SE, Movianto GmbH, Yourway Transport, Inc., Ancillare, LP, World Courier (Cencora, Inc.), Bionical Emas Ltd, Azenta Life Sciences, Inc., Kuehne+Nagel International AG, DHL Group, Clario, Inc., Suvoda LLC, 4G Clinical, LLC, Recipharm AB and Piramal Pharma Limited are the suppliers covered in Germany. The commercially relevant division is 28% of 2025 revenue in Storage and Distribution, where the volume is, against 10.84% growth in Supply Chain Management, where share moves. A supplier weighted toward Europe is competing over a base of USD 1.29 billion in 2025, reaching USD 2.69 billion by 2034 on the trajectory this study models.
United Kingdom
2nd-largest in Europe, growing 2.0×.
- In region 2 of 3
- Of region 20.9%
- Of global 5.9%
- Revenue $0.27B → $0.55B
The United Kingdom is sized at USD 0.27 billion in 2025, rising to USD 0.55 billion by 2034; 5.9% of global revenue and 20.9% of Europe. It is reported separately from Germany across every segmentation axis in the full report.
France
3rd-largest in Europe, growing 2.1×.
- In region 3 of 3
- Of region 14.7%
- Of global 4.1%
- Revenue $0.19B → $0.40B
4.1% of global revenue is generated in France; USD 0.19 billion in 2025, reaching USD 0.4 billion in 2034, and 14.7% of Europe.
Asia Pacific Market Analysis
The 3rd-largest region covered, and the one gaining the most — it picks up 4.2 points of share by 2034, while revenue still grows 2.6×.
- Rank 3 of 5
- 2025 share 21.8%
- By 2034 26%
- Revenue $1B → $2.59B
USD 1 billion of 2025 revenue is generated in Asia Pacific, 21.8% of the global clinical trial supplies market and reaches USD 2.59 billion by 2034. That makes it the third-largest region covered, in 2025 and again in 2034.
Share climbs to 26% by 2034, on growth above the market's own 9%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.
Segment composition follows the global pattern: Storage and Distribution largest at 28% of 2025 revenue, Supply Chain Management fastest at 10.84%. The full report breaks Asia Pacific out along every axis and by country.
China
The largest market in Asia Pacific, growing 2.9×.
- In region 1 of 3
- Of region 26%
- Of global 5.7%
- Revenue $0.26B → $0.75B
The largest single market in Asia Pacific is China, at USD 0.26 billion in 2025 and USD 0.75 billion in 2034. At 26% of the region in 2025 it leads, but a majority of Asia Pacific's revenue is generated in other markets. The region itself runs USD 1 billion to USD 2.59 billion over the same period, and this is the market carrying the country-level detail in the full report.
The service type pattern in China is the global one: 28% of 2025 revenue in Storage and Distribution, 27.5% by 2034, against 10.84% growth in Supply Chain Management taking it from 12% to 14%. Since 26% of Asia Pacific's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Per-service type revenue for China appears on its own in the full report.
In China the National Medical Products Administration regulates clinical trials through its Center for Drug Evaluation, which handles trial applications and implied approvals. Investigational products must be made in line with good manufacturing practice, and the trial itself follows the Chinese good clinical practice standard. Imported supplies need customs clearance and, for human biological material, additional oversight from the human genetic resources authorities. Labels must be in Chinese and mark the product as for clinical trial use only. Sponsors are expected to keep full quality and shipment records, and suppliers are audited against those expectations.
The suppliers tracked in this study (Thermo Fisher Scientific Inc., Catalent, Inc., Almac Group, PCI Pharma Services, Sharp Services, LLC, Marken Limited, Parexel International Corporation, Clinigen Group plc, Biocair International Ltd, Cryoport, Inc., Eurofins Scientific SE, Movianto GmbH, Yourway Transport, Inc., Ancillare, LP, World Courier (Cencora, Inc.), Bionical Emas Ltd, Azenta Life Sciences, Inc., Kuehne+Nagel International AG, DHL Group, Clario, Inc., Suvoda LLC, 4G Clinical, LLC, Recipharm AB and Piramal Pharma Limited) compete in China across the service type lines above. Storage and Distribution, at 28% of 2025 revenue, is where the volume sits, and Supply Chain Management, growing at 10.84%, is where position changes hands over the forecast period. The commercial size of that position is USD 1 billion in 2025 and USD 2.59 billion by 2034, 21.8% of the global total in the base year.
Japan
2nd-largest in Asia Pacific, growing 2.4×.
- In region 2 of 3
- Of region 21%
- Of global 4.6%
- Revenue $0.21B → $0.50B
4.6% of global revenue is generated in Japan; USD 0.21 billion in 2025, reaching USD 0.5 billion in 2034, and 21% of Asia Pacific.
India
3rd-largest in Asia Pacific, growing 4.2×.
- In region 3 of 3
- Of region 9%
- Of global 2%
- Revenue $0.09B → $0.38B
Within Asia Pacific, India accounts for 9% of regional revenue and 2% of the global total, worth USD 0.09 billion in 2025 and USD 0.38 billion by 2034.
Latin America Market Analysis
The 4th-largest region covered, holding its share flat through 2034, while revenue still grows 2.2×.
- Rank 4 of 5
- 2025 share 5.5%
- By 2034 5.5%
- Revenue $0.25B → $0.55B
In Latin America, 5.5% of global revenue puts 2025 at USD 0.25 billion on the way to USD 0.55 billion by 2034. That makes it the fourth-largest region covered, in 2025 and again in 2034.
By 2034 the share stands at 5.5%, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
Within the region the service type split tracks the global one; 28% of 2025 revenue in Storage and Distribution, fastest growth of 10.84% in Supply Chain Management. The full report breaks Latin America out along every axis and by country.
Brazil
The largest market in Latin America, growing 2.2×.
- In region 1 of 2
- Of region 36%
- Of global 2%
- Revenue $0.09B → $0.20B
The largest single market in Latin America is Brazil, at USD 0.09 billion in 2025 and USD 0.2 billion in 2034. Its 36% of base-year regional revenue leads the region, though enough sits elsewhere that Latin America is not a proxy for it. The region itself runs USD 0.25 billion to USD 0.55 billion over the same period, and this is the market carrying the country-level detail in the full report.
Composition here matches the global split: the largest line is Storage and Distribution at 28% of 2025 revenue, easing to 27.5% by 2034, and the fastest is Supply Chain Management at 10.84%, from 12% to 14%. Because the country carries 36% of Latin America, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. The full report reports Brazil by service type separately.
Brazil's health regulator, ANVISA, authorises clinical trials of drugs and biologics through a dossier for clinical development, while the national research ethics system reviews the protocol. Investigational products must be made under good manufacturing practice, with certification of the production site, and the study follows Brazilian good clinical practice rules. Imported supplies need an import authorisation tied to the approved protocol, and customs release depends on correct documentation. Labels are required in Portuguese and must identify the product as investigational. Suppliers must keep batch and distribution records available for inspection by the authority.
The suppliers tracked in this study (Thermo Fisher Scientific Inc., Catalent, Inc., Almac Group, PCI Pharma Services, Sharp Services, LLC, Marken Limited, Parexel International Corporation, Clinigen Group plc, Biocair International Ltd, Cryoport, Inc., Eurofins Scientific SE, Movianto GmbH, Yourway Transport, Inc., Ancillare, LP, World Courier (Cencora, Inc.), Bionical Emas Ltd, Azenta Life Sciences, Inc., Kuehne+Nagel International AG, DHL Group, Clario, Inc., Suvoda LLC, 4G Clinical, LLC, Recipharm AB and Piramal Pharma Limited) compete in Brazil across the service type lines above. Storage and Distribution, at 28% of 2025 revenue, is where the volume sits, and Supply Chain Management, growing at 10.84%, is where position changes hands over the forecast period. The commercial size of that position is USD 0.25 billion in 2025, moving to USD 0.55 billion by 2034 across the forecast period.
Mexico
2nd-largest in Latin America, growing 2.3×.
- In region 2 of 2
- Of region 24%
- Of global 1.3%
- Revenue $0.06B → $0.14B
1.3% of global revenue is generated in Mexico; USD 0.06 billion in 2025, reaching USD 0.14 billion in 2034, and 24% of Latin America.
Middle East and Africa Market Analysis
The 5th-largest region covered, holding its share flat through 2034, while revenue still grows 2.1×.
- Rank 5 of 5
- 2025 share 4.5%
- By 2034 4.5%
- Revenue $0.21B → $0.45B
Middle East and Africa holds 4.5% of the global clinical trial supplies market in 2025, worth USD 0.21 billion and reaches USD 0.45 billion by 2034. That makes it the fifth-largest region covered, in 2025 and again in 2034.
4.5% of global revenue sits here in 2034, below the 2025 level, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.
Within the region the service type split tracks the global one; 28% of 2025 revenue in Storage and Distribution, fastest growth of 10.84% in Supply Chain Management. Revenue for Middle East and Africa is broken out by every segmentation axis and by country in the full report.
South Africa
The largest market in Middle East and Africa, growing 2.0×.
- In region 1 of 2
- Of region 23.8%
- Of global 1.1%
- Revenue $0.05B → $0.10B
South Africa is the largest market within Middle East and Africa, generating USD 0.05 billion in 2025 and projected to reach USD 0.1 billion by 2034. It accounts for 23.8% of regional revenue in the base year, the largest single share without dominating the region outright. Set against USD 0.21 billion and USD 0.45 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
The service type pattern in South Africa is the global one: 28% of 2025 revenue in Storage and Distribution, 27.5% by 2034, against 10.84% growth in Supply Chain Management taking it from 12% to 14%. Its 23.8% weight in Middle East and Africa means those movements carry straight into the regional totals. Per-service type revenue for South Africa appears on its own in the full report.
In South Africa the South African Health Products Regulatory Authority oversees clinical trials and the products used in them. A sponsor applies for authorisation of the trial, and the protocol also goes to a registered research ethics committee. Investigational medicines must be made at sites licensed under good manufacturing practice, and import or export of supplies requires the relevant permits and licences. Labelling must identify the product as investigational and meet the authority's guidance on trial materials. The study follows national good clinical practice guidelines, so suppliers need reliable temperature control records and clear traceability from release to site.
Thermo Fisher Scientific Inc., Catalent, Inc., Almac Group, PCI Pharma Services, Sharp Services, LLC, Marken Limited, Parexel International Corporation, Clinigen Group plc, Biocair International Ltd, Cryoport, Inc., Eurofins Scientific SE, Movianto GmbH, Yourway Transport, Inc., Ancillare, LP, World Courier (Cencora, Inc.), Bionical Emas Ltd, Azenta Life Sciences, Inc., Kuehne+Nagel International AG, DHL Group, Clario, Inc., Suvoda LLC, 4G Clinical, LLC, Recipharm AB and Piramal Pharma Limited are the suppliers covered in South Africa. Two different problems sit on the same axis: holding Storage and Distribution at 28% of 2025 revenue, and taking Supply Chain Management while it grows at 10.84%. A supplier weighted toward Middle East and Africa is competing over a base of USD 0.21 billion in 2025 reaching USD 0.45 billion by 2034, 4.5% of global revenue at the start of that period.
Saudi Arabia
2nd-largest in Middle East and Africa, growing 2.3×.
- In region 2 of 2
- Of region 19%
- Of global 0.9%
- Revenue $0.04B → $0.09B
0.9% of global revenue is generated in Saudi Arabia; USD 0.04 billion in 2025, reaching USD 0.09 billion in 2034, and 19% of Middle East and Africa.
Download a free sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by service type, clinical phase, therapeutic area, drug type, temperature condition, route of administration, end user, trial design, delivery model, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Scale in Storage and Distribution and Growth in Supply Chain Management Set the Terms of Competition
Suppliers in scope: Thermo Fisher Scientific Inc., Catalent, Inc., Almac Group, PCI Pharma Services, Sharp Services, LLC, Marken Limited, Parexel International Corporation, Clinigen Group plc, Biocair International Ltd, Cryoport, Inc., Eurofins Scientific SE, Movianto GmbH, Yourway Transport, Inc., Ancillare, LP, World Courier (Cencora, Inc.), Bionical Emas Ltd, Azenta Life Sciences, Inc., Kuehne+Nagel International AG, DHL Group, Clario, Inc., Suvoda LLC, 4G Clinical, LLC, Recipharm AB and Piramal Pharma Limited.
The service type axis, not the regional one, is where competition happens. Storage and Distribution is 28% of 2025 revenue at USD 1.29 billion and still 27.5% in 2034, so it is where the volume sits and where an incumbent's position is hardest to move. Movement is concentrated in Supply Chain Management; 10.84% growth, against 8.15% at the other end of the axis in Packaging, Labeling and Kitting. A supplier positioned in one is not automatically positioned in the other, so a field of this size stays viable in a market of USD 4.6 billion.
Suppliers separate on their ability to keep investigational product intact and traceable across many countries at once. Depot scale, a validated cold and ultra-cold network and import licences in a wide set of countries decide who wins multi-region programs. Large providers add packaging, labeling, distribution and returns under one quality system, which suits sponsors running global Phase III studies. Smaller and regional players compete on speed, specialist handling for cell and gene therapies, flexible small-batch packaging and close service for biotechs with a single program. Direct-to-patient capability and integration with randomisation systems are becoming entry requirements.
The regional picture sets the entry cost: 40.2% of revenue is in North America and 28% in Europe, so a credible global position requires both, while Middle East and Africa at 4.5% can be served opportunistically.
Per-company profiles, financials, share and development history are in the full report and not here.
List of Key Clinical Trial Supplies Market Companies Profiled
24 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- Thermo Fisher Scientific Inc.(United States)
- Catalent, Inc.(United States)
- Almac Group(United Kingdom)
- PCI Pharma Services(United States)
- Sharp Services, LLC(United States)
- Marken Limited(United Kingdom)
- Parexel International Corporation(United States)
- Clinigen Group plc(United Kingdom)
- Biocair International Ltd(United Kingdom)
- Cryoport, Inc.(United States)
- Eurofins Scientific SE(Luxembourg)
- Movianto GmbH(Germany)
- Yourway Transport, Inc.(United States)
- Ancillare, LP(United States)
- World Courier (Cencora, Inc.)(United States)
- Bionical Emas Ltd(United Kingdom)
- Azenta Life Sciences, Inc.(United States)
- Kuehne+Nagel International AG(Switzerland)
- DHL Group(Germany)
- Clario, Inc.(United States)
- Suvoda LLC(United States)
- 4G Clinical, LLC(United States)
- Recipharm AB(Sweden)
- Piramal Pharma Limited(India)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 9 axes (Service Type, Clinical Phase, Therapeutic Area, Drug Type, Temperature Condition, Route of Administration, End User, Trial Design, Delivery Model), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 24 key companies, and the research methodology behind every estimate.
Segmentation
9 axes + regionQuestions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Clinical Trial Supplies Market projected to reach?
USD 9.96 USD Billion by 2034, CAGR 9%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 40.2% of global revenue through 2034.
05Which segment leads the market?
Storage and Distribution is the largest line by service type, at 28% of revenue in 2025.
06Who are the key companies profiled?
Thermo Fisher Scientific Inc., Catalent, Inc., Almac Group, PCI Pharma Services, Sharp Services, LLC, Marken Limited, Parexel International Corporation, Clinigen Group plc, Biocair International Ltd, Cryoport, Inc., Eurofins Scientific SE, Movianto GmbH, Yourway Transport, Inc., Ancillare, LP, World Courier (Cencora, Inc.), Bionical Emas Ltd, Azenta Life Sciences, Inc., Kuehne+Nagel International AG, DHL Group, Clario, Inc., Suvoda LLC, 4G Clinical, LLC, Recipharm AB, Piramal Pharma Limited. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.